Derma Sciences Inc. priced an underwritten public offering of 3.062 million shares of common stock at $10.34 per share, for net proceeds of about $29.3 million to support continued development of its candidate for diabetic foot ulcers, DSC127. Read More
The relationship between cancer, cancer treatments, inflammation and immunity had another layer of complexity added to it with the report this week that chemotherapy can contribute to promoting tumor growth via activating the inflammasome in some types of immune system cells, which ultimately led to angiogenesis. Read More
Privately held Naurex Inc. posted impressive Phase IIa results for lead antidepressant compound, GLYX-13, a partial agonist of the N-Methyl-D-Aspartate (NMDA) receptor, showing statistically significant reductions in depression scores in patients who had failed treatment with one or more antidepressant agents. Read More
• Arno Therapeutics Inc., of Flemington, N.J., has identified a new immunohistochemistry technique for identifying activated progesterone receptors in breast cancer tumors that may be predictive of response to treatment with onapristone, an investigational progestin receptor antagonist being developed by Arno that has demonstrated antitumor activity in preclinical and clinical studies. Read More
• Cytomedix Inc., of Gaithersburg, Md., said it signed an agreement with the National Institutes of Health to collaborate on a Phase II study in patients with intermittent claudication, which is caused by peripheral arterial disease. Read More
• Janssen Biotech Inc., of Horsham, Pa., and Janssen Biologics B.V., of Leiden, Netherlands, both part of Johnson & Johnson, submitted a supplemental biologics license application (sBLA) to the FDA and a Type II Variation to the European Medicines Agency (EMA) requesting approval of Stelara (ustekinumab) to treat adult patients with active psoriatic arthritis. Read More
• Two large, follow-up studies of Gardasil showed long duration of protection from human papillomavirus (HPV) resulting from HPV types 6, 11, 16 and 18, according to Sanofi Pasteur MSD, of Swiftwater, Pa., the vaccines division of Sanofi SA. Read More
